Bristol-Myers to sell AstraZeneca its stake in diabetes venture
Bristol-Myers Squibb Co. has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca. The company said Thursday that under the agreement, it will receive an upfront payment of $2.